Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALPNOTCMKTS:CNTTFNASDAQ:DMACNASDAQ:MBRXNASDAQ:ONTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.430.0%$39.38$6.71▼$64.57$4.23B1.141.90 million shs2.46 million shsCNTTFCannTrust$9.60$4.35▼$11.97$1.01B4.52528,025 shs1.43 million shsDMACDiaMedica Therapeutics$2.49-4.2%$2.85$1.50▼$4.75$94.52M1.6942,812 shs17,421 shsMBRXMoleculin Biotech$4.54+6.1%$7.07$4.28▼$15.75$10.12M1.9530,838 shs49,637 shsONTXOnconova Therapeutics$0.82$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences-0.05%+0.05%+61.28%+224.75%+763.67%CNTTFCannTrust0.00%0.00%0.00%0.00%0.00%DMACDiaMedica Therapeutics-4.23%-1.97%-11.70%-11.70%+44.77%MBRXMoleculin Biotech+6.07%-5.02%-42.22%-44.66%-62.17%ONTXOnconova Therapeutics0.00%0.00%+20.64%+44.71%+39.18%Now Open: Crypto emergency update (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune Sciences1.4845 of 5 stars2.13.00.00.03.14.20.0CNTTFCannTrustN/AN/AN/AN/AN/AN/AN/AN/ADMACDiaMedica Therapeutics0.9673 of 5 stars3.53.00.00.01.40.00.0MBRXMoleculin Biotech2.277 of 5 stars3.53.00.00.02.90.01.3ONTXOnconova Therapeutics0.7051 of 5 stars3.53.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences2.27Hold$50.33-21.88% DownsideCNTTFCannTrustN/AN/AN/AN/ADMACDiaMedica Therapeutics3.00Buy$7.00181.12% UpsideMBRXMoleculin Biotech3.00Buy$35.00670.93% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideCurrent Analyst RatingsLatest CNTTF, ONTX, MBRX, DMAC, and ALPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ALPNAlpine Immune SciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/12/2024ALPNAlpine Immune SciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $65.004/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/11/2024ALPNAlpine Immune SciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/11/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral4/11/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform4/9/2024ALPNAlpine Immune SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$58.88M71.73N/AN/A$5.64 per share11.42CNTTFCannTrust$15.96M0.00N/AN/AN/ANaNDMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)CNTTFCannTrustN/A$0.07137.180.00N/AN/AN/AN/AN/ADMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)Latest CNTTF, ONTX, MBRX, DMAC, and ALPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A 3/18/2024Q4 2023ALPNAlpine Immune Sciences-$0.32$0.15+$0.47$0.15$6.90 million$30.85 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/ACNTTFCannTrustN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A7.867.86CNTTFCannTrustN/AN/AN/ADMACDiaMedica TherapeuticsN/A19.2719.27MBRXMoleculin BiotechN/A3.863.86ONTXOnconova TherapeuticsN/A2.792.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%CNTTFCannTrust0.08%DMACDiaMedica Therapeutics10.12%MBRXMoleculin Biotech15.52%ONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%CNTTFCannTrustN/ADMACDiaMedica Therapeutics7.20%MBRXMoleculin Biotech6.70%ONTXOnconova Therapeutics3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences14265.55 million37.82 millionOptionableCNTTFCannTrustN/A105.61 millionN/ANot OptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableMBRXMoleculin Biotech152.23 million2.08 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableCNTTF, ONTX, MBRX, DMAC, and ALPN HeadlinesSourceHeadlineOnconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMOnconova and Trawsfynydd merge to form Traws Pharmauk.investing.com - April 4 at 6:50 PMTraws Pharma Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - April 4 at 6:50 PMNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynyddmsn.com - April 3 at 5:47 PMOnconova Acquires Trawsfynydd To Form Traws Pharmamarkets.businessinsider.com - April 2 at 10:00 AMTraws Pharma Announces New Employee Inducement Grantsglobenewswire.com - April 2 at 7:15 AMOnconova to Unveil New Rigosertib Study Results at Cancer Research Meetingmsn.com - March 12 at 8:48 AMAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)markets.businessinsider.com - March 11 at 1:17 PMOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024finance.yahoo.com - March 8 at 9:56 AMOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024globenewswire.com - March 8 at 8:00 AMOnconova Therapeutics Inc (ONTX)investing.com - February 13 at 12:22 AMOnconova Therapeutics, Inc. (ONTX)finance.yahoo.com - January 23 at 10:41 PMOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and Datesbenzinga.com - December 21 at 11:07 PMOnconova stock falls 10% on preclinical data for lymphoma drugmsn.com - December 12 at 4:02 PMOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphomafinance.yahoo.com - December 12 at 9:55 AMOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sfinance.yahoo.com - December 8 at 6:47 PMOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conferencefinance.yahoo.com - November 28 at 10:06 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 16 at 12:48 PMOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 16 at 1:30 AMOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 14 at 6:28 PMOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023finance.yahoo.com - November 7 at 5:22 PMOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLbenzinga.com - November 2 at 7:56 PMOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLfinance.yahoo.com - November 2 at 2:55 PMPromising Developments in Onconova Therapeutics’ Drug Narazaciclib Bolster Buy Rating: An Analysismarkets.businessinsider.com - October 19 at 3:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.CannTrustOTCMKTS:CNTTFCannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.